• news.cision.com/
  • Elekta/
  • GenesisCare makes major investment in Elekta cancer treatment equipment as it enters U.S. market

GenesisCare makes major investment in Elekta cancer treatment equipment as it enters U.S. market

Report this content

Elekta closes major order of around USD 200 million, including numerous linacs, service agreements and 11 Elekta Unity systems, surpassing the target of 75

ATLANTA, May 18, 2020 – Elekta (EKTA-B.ST) announced today that Australian-headquartered cancer care provider GenesisCare has ordered several Elekta linear accelerators (linacs) – of which 11 are Elekta Unity MR-Linac systems – to ensure that U.S. cancer clinics have the latest treatment solutions available. The total order value is around USD 200 million (approx. SEK 2 billion) over the next five years. The order value booked during the first quarter of Elekta’s fiscal year 2020/21 will be around USD 100 million (approx. SEK 1 billion).

GenesisCare announced the acquisition of major U.S. oncology services provider, 21st Century Oncology, in December 2019, marking its entry into the U.S. This follows GenesisCare’s successful expansion into Spain and the UK over the past five years. In announcing this recent acquisition, GenesisCare said it would invest USD 300 million in the U.S. including installation of state-of-the-art equipment.

Dan Collins, GenesisCare Founder and Chief Executive Officer, said: “Through our collaboration with 21st Century Oncology, we will have a global network of almost 200 treatment centers. Our goal is always to provide patients with high quality cancer care close to home, and we look forward to increasing access to innovative technology with Elekta. We’re especially excited to be introducing Unity to many regions in the U.S. and contributing to the body of clinical evidence demonstrating the huge potential of magnetic resonance radiation therapy.”

Unity is Elekta’s MR-Linac, a magnetic resonance radiation therapy (MR/RT) system that enables personalized precision radiation therapy through real-time MR imaging of the tumor during treatment. With this order, Elekta exceeds the target of 75 Unity orders by mid-year 2020, reaching a current total of 80 Unity orders.  

“We are very happy to extend our longstanding relationship with GenesisCare as it builds up its presence in the United States,” said Richard Hausmann, Elekta’s President and CEO. “Their high ambitions in precision radiation medicine goes well together with ours. This will enable GenesisCare to offer the best outcomes to their cancer patients.”

The first deliveries of the order are planned for July 2020.

# # #

For further information, please contact:
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail:
Time zone: CET: Central European Time

Mattias Thorsson, Head of Corporate Communications and Public Affairs
Tel: +46 70 865 8012, e-mail: 
Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on May 18, 2020. (REGMAR)

About Unity
Elekta Unity is a state-of-the art MR-Linac that is defining a new standard for personalized radiation therapy based on real-time high resolution anatomical and biological MRI at the point-of-care. Unity combines a Philips high-field 1.5T MRI scanner with a best-in-class 7MV linear accelerator and breakthrough online dose replanning software that are fully integrated to enable adaptive radiotherapy and real-time target monitoring.

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.



Documents & Links